Hormonal
GLP-1 receptor agonists significantly increase the likelihood of achieving weight loss compared to placebo, with tirzepatide and semaglutide demonstrating the highest relative efficacy among evaluated agents.
If you have obesity or overweight with related health issues, GLP-1 receptor agonists like semaglutide or tirzepatide are highly effective pharmacological options. They work by mimicking a hormone that reduces hunger and slows digestion. Clinical data shows they significantly increase the chance of losing weight compared to placebo, with tirzepatide and semaglutide showing the best results. These medications are FDA-approved for chronic weight management and should be used in combination with lifestyle changes.
GLP-1 receptor agonists significantly increase the likelihood of weight loss versus placebo, with tirzepatide and semaglutide demonstrating the greatest relative efficacy among agents evaluated.
Why this rating
Based on a systematic review and meta-analysis of 21 randomized controlled trials involving 7024 participants.
Source
GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials
Nehad Ahmad et al. · Medicine · 2026
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →